These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6112654)

  • 1. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose.
    Home PD; Pickup JC; Keen H; Alberti KG; Parsons JA; Binder C
    Metabolism; 1981 May; 30(5):439-42. PubMed ID: 6112654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man.
    Waldhäusl WK; Bratusch-Marrain PR; Vierhapper H; Nowotny P
    Metabolism; 1983 May; 32(5):478-86. PubMed ID: 6341763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre- and postprandial hyperinsulinemia during insulin pump treatment; role of the subcutaneous bolus and basal infusion.
    Olsson PO; Jorfeldt L; Arnqvist H; Gerhardsson P
    Diabetes Res; 1991 Feb; 16(2):55-61. PubMed ID: 1817806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy.
    Kraegen EW; Chisholm DJ
    Clin Pharmacokinet; 1985; 10(4):303-14. PubMed ID: 3899451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion.
    Lager I; Lönnroth P; von Schenck H; Smith U
    Br Med J (Clin Res Ed); 1983 Dec; 287(6406):1661-4. PubMed ID: 6416540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between multi-injection and continuous subcutaneous insulin therapy in insulin-dependent diabetic inpatients.
    Saibene V; Melandri M; Brembilla L; Spotti D; Pozza G
    Acta Diabetol Lat; 1981; 18(1):45-50. PubMed ID: 7010856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group.
    Kelley DE; Henry RR; Edelman SV
    Diabetes Care; 1996 Nov; 19(11):1237-42. PubMed ID: 8908387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma insulin and C-peptide levels during continuous subcutaneous insulin infusion.
    Slama G; Buu KN; Tchobroutsky G; Delage A; Desplanque N
    Diabetes Care; 1979; 2(3):251-5. PubMed ID: 510116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin oscillations per se do not affect glucose turnover parameters in normal man.
    Paolisso G; Scheen AJ; Verdin EM; Luyckx AS; Lefebvre PJ
    J Clin Endocrinol Metab; 1986 Aug; 63(2):520-5. PubMed ID: 3522623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual-wave bolus feature in continuous subcutaneous insulin infusion pumps controls prolonged post-prandial hyperglycaemia better than standard bolus in Type 1 diabetes.
    Lee SW; Cao M; Sajid S; Hayes M; Choi L; Rother C; de León R
    Diabetes Nutr Metab; 2004 Aug; 17(4):211-6. PubMed ID: 15575341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programming of insulin delivery with meals during subcutaneous insulin infusion.
    Chisholm DJ; Kraegen EW; Zelenka GS
    Diabetes Care; 1981; 4(2):265-8. PubMed ID: 7011744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma insulin and C-peptide after subcutaneous and intravenous administration of human insulin (recombinant DNA) and purified porcine insulin in healthy men.
    Pickup JC; Bilous RW; Viberti GC; Keen H; Jarrett RJ; Glynne A; Cauldwell J; Root M; Rubenstein AH
    Diabetes Care; 1982; 5 Suppl 2():29-34. PubMed ID: 6765536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach.
    Nosadini R; De Kreutzenberg S; Duner E; Iori E; Avogaro A; Trevisan R; Fioretto P; Doria A; Merkel C; Cobelli C
    J Clin Endocrinol Metab; 1988 Sep; 67(3):551-9. PubMed ID: 3045144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin plasma levels and biological effects following subcutaneous administration of somatostatin in man.
    Uccioli L; Ghirlanda G; Cotroneo P; Manto A; Solini A; Greco AV
    Acta Endocrinol (Copenh); 1986 Dec; 113(4):465-70. PubMed ID: 2878551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies.
    Kraegen EW; Chisholm DJ
    Diabetologia; 1984 Mar; 26(3):208-13. PubMed ID: 6370771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects.
    Burke B; Andrews WJ; Hadden DR
    Diabetes Res; 1987 Apr; 4(4):163-7. PubMed ID: 3304782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.